@IDimaandalMD Profile picture

Ian Limuel Dimaandal

@IDimaandalMD

PGY - 5 Multiple Sclerosis. @bcmneurology. @UConnNeurology Alumni. Federer Forever. 🇵🇭. New Account

Ian Limuel Dimaandal Reposted

Ocrevus and rituximab don't work in primary progressive MS? This French Observational study of 1,184 people found those taking these drugs had similar rates of disability progression (when correcting for other confounders) than people not taking them. neurology.org/doi/10.1212/WN…


Ian Limuel Dimaandal Reposted

HERCULES!

Tweet Image 1

Ian Limuel Dimaandal Reposted

Jacob Loeffler MD @Stanford_Neuro presents EBV-related mechanisms of autoimmunity in MS @nmss @mssociety

Tweet Image 1

Ian Limuel Dimaandal Reposted

NMOSD & MOGAD: An evolving spectrum What an insightful article @NatRevNeurol doi.org/10.1038/s41582…

Tweet Image 1
Tweet Image 2
Tweet Image 3

Ian Limuel Dimaandal Reposted

Heinz Wiendl (Ge) presenting biomarkers post-cladribine treatment (MAGNIFY study). Immune reconstitution towards more homeostatic and less pathogenic status. Also effects on OCBs in csf were seen! More effects on B-cells This shows real immune changes 💪🏻 #ECTRIMS2024

Tweet Image 1

Ian Limuel Dimaandal Reposted

Your roadmap for Autoimmune Encephalitis. A useful slide being shared from our UK Childhood Neuroinflammatory Disorders meeting, put together by Dr Michael Eyre.

Tweet Image 1

Ian Limuel Dimaandal Reposted

Thouvenot: Largest therapeutic trial of vitamin D therapy in #MS. Oral vitamin D 100,000 IU every two weeks reduced disease activity by 34% in CIS patients and in early RRMS. #ECTRIMS2024

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Ian Limuel Dimaandal Reposted

Bove: SOPRANINO study. Ocrelizumab Ocrevus was undetectable in blood of infants being nursed by mothers with MS being treated with this monoclonal antibody. Also, B cell counts in newborns were reassuringly normal (important for infant vaccines). #ECTRIMS2024

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Ian Limuel Dimaandal Reposted

New McDonald Criteria for diagnosis MS. @XMontalban: New criteria includes RIS under certain circumstances, central vein sign, neurofilament light chain and optic nerve. #ECTRIMS2024

Tweet Image 1
Tweet Image 2
Tweet Image 3
Tweet Image 4

Ian Limuel Dimaandal Reposted

Corpus callosum involvement in MOG antibody-associated disease in comparison to AQP4-IgG-seropositive neuromyelitis optica spectrum disorder and multiple sclerosis 🧠🦠👌journals.sagepub.com/doi/10.1177/13…

Tweet Image 1

Ian Limuel Dimaandal Reposted

A #TWEETORIAL based on a @radiology_rsna article, A🧵: 1/10 Autoimmune encephalitis (AE) is not rare! one study showed that among persons<30 years old AE was more common than any single infectious cause 🤯 Even HSV-1! Here are some common imaging patterns from @TheAJNR

Tweet Image 1

Ian Limuel Dimaandal Reposted

New #open access paper @GreenJournal shows CD138 as new biomarker for #MS and extend CD27 as a marker of CSF inflammation. These biomarkers may refine, in the future, our ability to diagnose early and individualized management. pubmed.ncbi.nlm.nih.gov/38669615/

Tweet Image 1

Ian Limuel Dimaandal Reposted

Extending about 9 weeks the interval dosing of ocrelizumab in #MultipleSclerosis did not result in clinical, radiological, or biomarker evidence of worsening. Prospective, double-arm, open-label, multi-center study in 🇩🇰 @UniSouthDenmark ▶️ journals.sagepub.com/doi/10.1177/13…

Tweet Image 1

Ian Limuel Dimaandal Reposted

Radiologically isolated syndrome in the spectrum of #MultipleSclerosis: Implications in the clinical management of individuals with asymptomatic multiple sclerosis. Review from @UCSF_MS_Center @UTSWMedCenter @XtineLebrunF @Univ_CotedAzur ▶️ journals.sagepub.com/doi/full/10.11…

Tweet Image 1

Ian Limuel Dimaandal Reposted

Treatment of refractory MOG–antibody-associated disease #MOGAD can be challenging. Here, autologous hematopoietic stem cell transplantation (aHSCT) was safe and able to suppress disease-activity for over 2 years. Case from @MatildeInglese @UniGenova ▶️ journals.sagepub.com/doi/full/10.11…

Tweet Image 1

Ian Limuel Dimaandal Reposted

pls RT 📢I’m attending #AANAM April 13-18. Will you be joining me at my #neurology Course C47 - Diagnosis and Treatment of Multiple Sclerosis in Diverse Populations on Sunday 04/14/14 together with Drs @NerdyNeuroMD and Lilyana Amezcua @AANbrain @mssociety @uconnhealth @mscare

Tweet Image 1
Tweet Image 2

Ian Limuel Dimaandal Reposted

Excellent article! @Mayo_AING #Radiological differences between #autoimmune #encephalitis (#LGI1/#CASPR2), VE (viral) & #CJD 38% EA normal MRI: Isolated involvement amygdala/hippocampus Without hemorrhage Without DWI restriction or Gd enhancement (Is very rare) #NeuroTwitter

Tweet Image 1

Ian Limuel Dimaandal Reposted

After 27 months from bexarotene treatment, visual evoked potential latency remained improved, thus suggesting long-term remyelinating benefits. A follow-up study of the Cambridge Centre for Myelin Repair One trial from @NickGCunniffe @CambridgeMS1 ▶️ journals.sagepub.com/doi/full/10.11…

Tweet Image 1

Ian Limuel Dimaandal Reposted
Tweet Image 1

Ian Limuel Dimaandal Reposted

📢March issue is now available ▶️ journals.sagepub.com/toc/MSJ/current ...and the cover goes to @DanOntaneda @CCLRI @CleClinicMD @CLENeurons showing the effect of ibudilast on slowly enlarging lesions in progressive #MultipleSclerosis ▶️ journals.sagepub.com/doi/10.1177/13…

Tweet Image 1

United States Trends
Loading...

Something went wrong.


Something went wrong.